Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Mycosis Fungoides 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Familial ependymoma 1

Interventions

Fluorouracil 67Leucovorin 61Oxaliplatin 49Irinotecan 31Capecitabine 23Cetuximab 22Bevacizumab 20Folfox protocol 13Radiotherapy 12Chemotherapy, Adjuvant 11Neoadjuvant Therapy 10Erlotinib Hydrochloride 7dehydroftorafur 5Trastuzumab 5Radiation 5Melphalan 5Magnetic Resonance Spectroscopy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5sargramostim 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Gene Expression Profiling 4Gefitinib 4Floxuridine 4Biopsy 4aldesleukin 3Sorafenib 3Semaxinib 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rectal Neoplasms × becatecarin × Clear all
NCT00005085 2013-02-11

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡